Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 63 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
FEBELCO from Sint-Niklaas, company number BE0458780306, closed financial year 2025 with a result of € 4.4 million after tax. For that financial year FEBELCO recorded revenue of € 1.8 billion and equity of € 103.6 million. Compared with financial year 2024, the result moved from € 4.2 million to € 4.4 million. Profitable, and profit is growing. The company holds a healthy buffer. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on May 20, 2026.
€ 103.6 million
▼ 11% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 4.4 million
▲ 6% vs 2024
Profit after tax over the fiscal year.
€ 226,339
▼ 24% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 34.5 million.
People and assets in 2025
948.1
▼ 49.7 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 64.9 million
▲ 5% vs 2024
€ 68,400 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 1.8 million
▲ 32% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 78 million
▲ 33% vs 2024
€ 4 million is repaid this year. At this pace the long-term loan is gone in ≈ 8 years.
€ 156.6 million
▲ 5% vs 2024
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 33 days on average.
€ 15.7 million
▲ 15% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | € 1,646,853,216 | € 1,693,413,079 | € 1,716,959,829 | € 1,788,913,420 | ▲ 4% |
| Profit after taxes | € 1,046,514 | € 7,276,022 | € 4,184,115 | € 4,420,212 | ▲ 6% |
| Equity | € 129,435,265 | € 124,587,095 | € 116,111,614 | € 103,583,646 | ▼ 11% |
| Total debts | € 259,416,947 | € 252,248,283 | € 247,100,036 | € 273,370,312 | ▲ 11% |
| Cash | € 1,467,322 | € 1,016,558 | € 296,732 | € 226,339 | ▼ 24% |
| Land & buildings | € 42,186,444 | € 39,687,218 | € 37,857,303 | € 36,059,515 | ▼ 5% |
| Retained profit | € 50,062,389 | € 47,721,779 | € 42,105,962 | € 34,538,470 | ▼ 18% |
| Bank debt | € 68,126,183 | € 72,040,439 | € 58,536,737 | € 78,019,679 | ▲ 33% |
| Balance sheet total | € 393,608,790 | € 381,621,485 | € 368,002,251 | € 381,864,666 | ▲ 4% |
| Employees (FTE) | 914 | 963.9 | 997.8 | 948.1 | ▼ 49.7 |
Key figures of FEBELCO, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to FEBELCO?
What happened at FEBELCO in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Hannelore Walcarius stepped down as director. NBB
- Michel De Ridder stepped down as director. NBB
- Klaas Debruyne stepped down as director. NBB
- Nicolas Meuwissen stepped down as director. NBB
- Aristo BV stepped down as director. NBB
- Eric Van Nueten stepped down as director. NBB
- Kathleen Vermylen stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 4.4 million (▲ 6% vs 2024). Source: NBB ↗
In short
From € 1 million profit in 2022 to € 4.4 million profit in 2025.
Paid € 6.8 million in corporate taxes since 2022.
Best year ever: 2023, with € 7.3 million profit.
Pays suppliers within 33 days on average.
A new publication or filing at FEBELCO? We notify you, reason included.
Follow FEBELCODatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of PHARMACIE BIA, PHARMACIE DU PETIT CHAMP, Frenaver, PHARMACIE RINCHARD VALERIE, APOTHEEK DE STATIE, Apotheek Vijve comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
FEBELCOThe shares are held by PHARMACIE BIA (100%), PHARMACIE DU PETIT CHAMP (2%), Frenaver (2%), PHARMACIE RINCHARD VALERIE (0%), APOTHEEK DE STATIE and Apotheek Vijve. It owns 100% of Sodiap, 100% of Livlina, 99.9% of Axone Pharma, 99.8% of Febelfarma, 49% of Pannoc Chemie and 37.5% of Medipim itself.
Directors
According to the 2025 annual accounts
since 2022 · until 2028
since 2024 · until 2030
since 2024 · until 2030
Managing director · represented by Olivier Delaere
Also active at: SDC, HC Pharma, SODIAP, APOTHEEK JENNE, PANNOC CHEMIE, Apotheek de Lisseweg, Apotheek Seurinck, APOTHEEK SCARPHOUT +34 more
since 2020 · until 2026
Kathleen Vermylen
Director
since 2021 · until 2027
Klaas Debruyne
Director
since 2024 · until 2030
Johan Lamoot
Director
Also active at: Immo Falam, APOTHEEK LAMOOT, APOVLAM, LES AMIS DE NORBERT, PhiDeX Inc.
since 2020 · until 2026
Chairman of the board · represented by Frank Coene
Also active at: LIVLINA, FEBELFARMA, FEBELCOFONDS, AXONE PHARMA, LIVLINA TRANSPORT
since 2022 · until 2028
Eric Van Nueten
Director
Also active at: APOTHEEK MOLENVELD, FEBELFARMA, FEBELCOFONDS, EVN CONSULTING, E.V.N. PHARMA
since 2022 · until 2028
Shareholders
Participations
Establishments
Establishment units
Physical locations of this company
Eigenlostraat 1
9100 Sint-Niklaas
Baron de Grubenlaan 3
2110 Wijnegem
Active since 22 April 2002
Gotevlietstraat 94
8000 Brugge
Active since 27 May 2002
Noordkaai 9
8870 Izegem
Active since 4 July 2002
Jan-Baptist Vinkstraat 3
3070 Kortenberg
Active since 4 July 2002
Pachtgoedstraat 10
9100 Sint-Niklaas
Active since 17 May 2002
Dellestraat 57
3550 Heusden-Zolder
Active since 29 January 2014
Rue de l'Europe 3
7080 Frameries
Active since 1 July 2021
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 4 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0458.780.306
- VAT number
- BE 0458.780.306
- Registered office
- Eigenlostraat 1, 9100 Sint-Niklaas
- Names & denominations
- FEBELCO
- Enterprise type
- Rechtspersoon
- Legal form
- Cooperative company
- Legal situation
- Normale toestand
- Start date
- 11 September 1996
- Peppol
- Active · Active since 1 Jan 2001
- Contact
- [email protected]
- Activities · NACE
Groothandel in farmaceutische en medische artikelen
Groothandel in farmaceutische producten
Groothandel in reinigingsmiddelen
Groothandel in andere voedingsmiddelen, neg
Groothandel in parfumerieën en cosmetica
Groothandel in behang en onderhoudsproducten
Overige gespecialiseerde groothandel in voedingswaren